Correlation Between Esperion Therapeutics and Alnylam Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Esperion Therapeutics and Alnylam Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Esperion Therapeutics and Alnylam Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Esperion Therapeutics and Alnylam Pharmaceuticals, you can compare the effects of market volatilities on Esperion Therapeutics and Alnylam Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Esperion Therapeutics with a short position of Alnylam Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Esperion Therapeutics and Alnylam Pharmaceuticals.

Diversification Opportunities for Esperion Therapeutics and Alnylam Pharmaceuticals

0.69

Correlation Coefficient

Esperion Therapeutics  Alnylam Pharmaceuticals

Poor diversification

The 3 months correlation between Esperion and Alnylam is 0.69. Overlapping area represents the amount of risk that can be diversified away by holding Esperion Therapeutics and Alnylam Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Alnylam Pharmaceuticals and Esperion Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Esperion Therapeutics are associated (or correlated) with Alnylam Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Alnylam Pharmaceuticals has no effect on the direction of Esperion Therapeutics i.e., Esperion Therapeutics and Alnylam Pharmaceuticals go up and down completely randomly.

Pair Corralation between Esperion Therapeutics and Alnylam Pharmaceuticals

Given the investment horizon of 90 days Esperion Therapeutics is expected to generate 1.86 times more return on investment than Alnylam Pharmaceuticals. However, Esperion Therapeutics is 1.86 times more volatile than Alnylam Pharmaceuticals. It trades about 0.19 of its potential returns per unit of risk. Alnylam Pharmaceuticals is currently generating about 0.25 per unit of risk. If you would invest  87.00  in Esperion Therapeutics on May 7, 2025 and sell it today you would earn a total of  62.00  from holding Esperion Therapeutics or generate 71.26% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Esperion Therapeutics  vs.  Alnylam Pharmaceuticals

Esperion Therapeutics

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Esperion Therapeutics are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Esperion Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.

Alnylam Pharmaceuticals

Risk-Adjusted Performance

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Alnylam Pharmaceuticals are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Alnylam Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Esperion Therapeutics and Alnylam Pharmaceuticals

The main advantage of trading using opposite Esperion Therapeutics and Alnylam Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Esperion Therapeutics position performs unexpectedly, Alnylam Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alnylam Pharmaceuticals will offset losses from the drop in Alnylam Pharmaceuticals' long position.

The idea behind Esperion Therapeutics and Alnylam Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.